Le Burel et al. [93] reported that out of 908 patients who received anti-PD-1/PD-L1 treatment, the estimated prevalence of Sjogren syndrome was 0.3%, while it increased to 2.5% among patients treated with the combined use of ICIs. Here, CD274 is linked to Sjogren syndrome.